A simple formula for individualising ceftazidime dosage administered by continuous infusion in patients with haematological malignancies - PubMed (original) (raw)

Randomized Controlled Trial

A simple formula for individualising ceftazidime dosage administered by continuous infusion in patients with haematological malignancies

Eric Dailly et al. Int J Antimicrob Agents. 2006 Jun.

Abstract

A formula is proposed for individualising ceftazidime dosage administered by continuous infusion in patients with haematological malignancies. Sixty patients were retrospectively randomised into Group A (n=30) to establish the formula and Group B (n=30) to evaluate this formula. Individual ceftazidime clearances were estimated from the ratio between the rate of infusion and plasma concentration at steady state. In Group A, ceftazidime clearance was significantly correlated with creatinine clearance. From this result, a formula (rate of infusion (g/day)=0.00133x[creatinine clearance (mL/min)]x[target concentration at steady state (mg/L)]) is proposed. This formula provided consistent estimations of ceftazidime plasma concentrations in Group B and should help clinicians to define the optimum ceftazidime dosage, particularly in patients with disturbed renal function.

PubMed Disclaimer

Similar articles

Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients.
Dailly E, Le Floch R, Deslandes G, Pannier M, Jolliet P. Dailly E, et al. Int J Antimicrob Agents. 2008 Jun;31(6):537-9. doi: 10.1016/j.ijantimicag.2008.02.008. Epub 2008 May 6. Int J Antimicrob Agents. 2008. PMID: 18462925
[Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
Cousson J, Floch T, Vernet-Garnier V, Appriou M, Petit JS, Jovenin N, Lamiable D, Hoizey G. Cousson J, et al. Pathol Biol (Paris). 2005 Oct-Nov;53(8-9):546-50. doi: 10.1016/j.patbio.2005.06.002. Epub 2005 Jul 14. Pathol Biol (Paris). 2005. PMID: 16023303 Clinical Trial. French.
Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
Lorente L, Jiménez A, Palmero S, Jiménez JJ, Iribarren JL, Santana M, Martín MM, Mora ML. Lorente L, et al. Clin Ther. 2007 Nov;29(11):2433-9. doi: 10.1016/j.clinthera.2007.11.003. Clin Ther. 2007. PMID: 18158083
[Pharmacodynamic optimization of ceftazidime against Pseudomonas aeruginosa: continuous infusion or intermittent administration?].
Aguilar L, Giménez MJ, Martín JE, Prieto J. Aguilar L, et al. Rev Esp Quimioter. 2005 Mar;18(1):21-5. Rev Esp Quimioter. 2005. PMID: 15915228 Review. Spanish. No abstract available.
Ceftazidime stability and pyridine toxicity during continuous i.v. infusion.
Jones TE, Selby PR, Mellor CS, Cheam DB. Jones TE, et al. Am J Health Syst Pharm. 2019 Feb 1;76(4):200-205. doi: 10.1093/ajhp/zxy035. Am J Health Syst Pharm. 2019. PMID: 30715181 Review.

Cited by

Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?
Pea F, Viale P. Pea F, et al. Crit Care. 2009;13(3):214. doi: 10.1186/cc7774. Epub 2009 Jun 10. Crit Care. 2009. PMID: 19519961 Free PMC article. Review.

A simple formula for individualising ceftazidime dosage administered by continuous infusion in patients with haematological malignancies - PubMed (original) (raw)